|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNRD1 |
Gene summary for ZNRD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNRD1 | Gene ID | 30834 |
| Gene name | RNA polymerase I subunit H | |
| Gene Alias | A12.2 | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q2L6J2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 30834 | ZNRD1 | LZE4T | Human | Esophagus | ESCC | 3.86e-24 | 6.76e-01 | 0.0811 |
| 30834 | ZNRD1 | LZE5T | Human | Esophagus | ESCC | 4.53e-04 | 5.15e-01 | 0.0514 |
| 30834 | ZNRD1 | LZE7T | Human | Esophagus | ESCC | 7.68e-11 | 6.07e-01 | 0.0667 |
| 30834 | ZNRD1 | LZE8T | Human | Esophagus | ESCC | 2.82e-19 | 5.19e-01 | 0.067 |
| 30834 | ZNRD1 | LZE20T | Human | Esophagus | ESCC | 6.67e-17 | 4.94e-01 | 0.0662 |
| 30834 | ZNRD1 | LZE22D1 | Human | Esophagus | HGIN | 6.96e-07 | 1.97e-01 | 0.0595 |
| 30834 | ZNRD1 | LZE22T | Human | Esophagus | ESCC | 6.32e-06 | 7.32e-01 | 0.068 |
| 30834 | ZNRD1 | LZE24T | Human | Esophagus | ESCC | 1.35e-25 | 7.43e-01 | 0.0596 |
| 30834 | ZNRD1 | LZE21T | Human | Esophagus | ESCC | 1.85e-04 | 5.63e-01 | 0.0655 |
| 30834 | ZNRD1 | LZE6T | Human | Esophagus | ESCC | 4.79e-13 | 7.64e-01 | 0.0845 |
| 30834 | ZNRD1 | P1T-E | Human | Esophagus | ESCC | 1.70e-10 | 7.18e-01 | 0.0875 |
| 30834 | ZNRD1 | P2T-E | Human | Esophagus | ESCC | 1.91e-59 | 1.18e+00 | 0.1177 |
| 30834 | ZNRD1 | P4T-E | Human | Esophagus | ESCC | 2.03e-52 | 1.17e+00 | 0.1323 |
| 30834 | ZNRD1 | P5T-E | Human | Esophagus | ESCC | 1.76e-21 | 3.38e-01 | 0.1327 |
| 30834 | ZNRD1 | P8T-E | Human | Esophagus | ESCC | 2.32e-54 | 1.06e+00 | 0.0889 |
| 30834 | ZNRD1 | P9T-E | Human | Esophagus | ESCC | 3.18e-17 | 3.31e-01 | 0.1131 |
| 30834 | ZNRD1 | P10T-E | Human | Esophagus | ESCC | 1.09e-52 | 8.39e-01 | 0.116 |
| 30834 | ZNRD1 | P11T-E | Human | Esophagus | ESCC | 1.06e-18 | 4.72e-01 | 0.1426 |
| 30834 | ZNRD1 | P12T-E | Human | Esophagus | ESCC | 4.84e-50 | 9.15e-01 | 0.1122 |
| 30834 | ZNRD1 | P15T-E | Human | Esophagus | ESCC | 4.71e-29 | 6.17e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNRD1 | SNV | Missense_Mutation | c.316G>T | p.Asp106Tyr | p.D106Y | Q9P1U0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNRD1 | SNV | Missense_Mutation | novel | c.159N>T | p.Lys53Asn | p.K53N | Q9P1U0 | protein_coding | tolerated(0.27) | benign(0.051) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZNRD1 | SNV | Missense_Mutation | novel | c.372A>C | p.Glu124Asp | p.E124D | Q9P1U0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNRD1 | SNV | Missense_Mutation | novel | c.160N>A | p.Val54Ile | p.V54I | Q9P1U0 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ZNRD1 | SNV | Missense_Mutation | novel | c.218N>C | p.Glu73Ala | p.E73A | Q9P1U0 | protein_coding | tolerated(0.21) | benign(0) | TCGA-BR-7704-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNRD1 | SNV | Missense_Mutation | c.257N>A | p.Arg86His | p.R86H | Q9P1U0 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |